Beijing Huafang Investment
VC Fund
Beijing, China
Beijing Huafang Investment is a VC fund in Beijing focused on Biotechnology and Medical. Beijing Huafang Investment focuses on the investment and management of state-owned capital and its investment covers commercial real estate.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Beijing Huafang Investment invests in
Stages Beijing Huafang Investment invests in
Countries Beijing Huafang Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $13M–$14M
- Series A
- $14M–$30M
Investment Focus
Industry
- Biotechnology 12 (44%)
- Medical 10 (37%)
- Biopharma 6 (22%)
- Health Care 6 (22%)
- Manufacturing 4 (15%)
Stage
- Series A 10 (37%)
- Seed 6 (22%)
- Angel 5 (19%)
- Series B 1 (4%)
- Series C 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Lu Chi
Partner
|
Partner | Total investments: 2 | Find email | |
|
Wangqian Luo
partner
|
partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Glimmer Gene develops a comprehensive gene editing and epigenetic toolkit with independent intellectual property rights. | Seed / Sep 09, 2026 | ||
| ClonOrgan has developed a technology to humanize pig cells that will grow into human-compatible organs.The business specializes in xenotransplantation and has a one-stop R&D platform that includes raising gene-edited pigs, preclinical testing, and breeding. It is dedicated to addressing the critical shortage of clinical organ transplantationand creating the organ factory of the future.ClonOrgas was established in 2005 in Chengdu, Sichuan. | Series A / Aug 07, 2026 | ||
| Kaiwang Data is a one-stop shop for data solutions. It focuses on offering complete data labeling solutions for automakers and businesses involved in autonomous driving. | $14.8M / Venture - Series Unknown / Aug 04, 2026 | ||
| Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. | Series A / Jun 26, 2026 | ||
| Q1 2022 c-suite not found. | $14.8M / Jun 18, 2026 | ||
| Mindtrix (明视脑机) develops brain–computer‑interface technology focused on reconstructing visual information and neural signals from the brain, primarily for visual‑reconstruction and implantable‑BCI applications. It conducts research and builds systems to decode brain‑wave patterns and translate them into machine‑interpretable outputs, aiming atadvanced neurotechnology and human–machine interfaces. The company also works on underlying hardware and software platforms that support high‑precision neural data acquisition, processing, and real‑time feedback loops. | $21.8M / Angel / Apr 02, 2026 | ||
| Neurodome is a manufacturer of non-invasive deep brain nerve modulation technology. It focuses on the research and development of non-invasive deep brain nerve modulation products. | $14.5M / Series A / Mar 12, 2026 | ||
|
Ruishi Biotechnology
|
Ruishi Biotechnology focuses on cell therapy drug development, aiming to address significant unresolved clinical needs in the field of ophthalmic diseases. | Angel / Nov 13, 2025 | |
|
Jiaweida Biotechnology
|
Jiaweida Biotechnology is a manufacturing company developing collagens, peptides, and raw materials for the cosmetics industry. | Series A / Aug 19, 2025 | |
| Neurodome is a manufacturer of non-invasive deep brain nerve modulation technology. It focuses on the research and development of non-invasive deep brain nerve modulation products. | Series A / Feb 24, 2025 | ||
| See all 27 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Beijing Huafang Investment invest in?
Beijing Huafang Investment invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series A and Seed stage. Most of the 27 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Beijing Huafang Investment's check size?
Beijing Huafang Investment typically joins rounds of $13M–$14M at Seed and $14M–$30M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Beijing Huafang Investment participates in.
How do I contact Beijing Huafang Investment?
Public channels for Beijing Huafang Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Beijing Huafang Investment?
The team at Beijing Huafang Investment includes Lu Chi (Partner) and Wangqian Luo (partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
